BDULF (Bangkok Dusit Medical Services PCL) Research & Development: $0 Mil (TTM As of Mar. 2026)


BDULF Bangkok Dusit Medical Services PCL BDULF
65 GF Score
Price $0.56
GF Value $0.98
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Bangkok Dusit Medical Services PCL Research & Development?

Bangkok Dusit Medical Services PCL BDULF 65 Research & Development is $0 Mil as of Mar. 2026. GuruFocus rates BDULF with a GF Score™ of 65/100 and a GF Value™ of $0.98 (Significantly Undervalued). The stock has 2 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Bangkok Dusit Medical Services PCL's Research & Development for the three months ended in Mar. 2026 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0 Mil.

Bangkok Dusit Medical Services PCL  (OTCPK:BDULF) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Bangkok Dusit Medical Services PCL Research & Development Related Terms

Bangkok Dusit Medical Services PCL Research & Development Historical Data

* Premium members only.

The historical data trend for Bangkok Dusit Medical Services PCL's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bangkok Dusit Medical Services PCL Research & Development Chart

Bangkok Dusit Medical Services PCL Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bangkok Dusit Medical Services PCL Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BDULF
65GF Score
Bangkok Dusit Medical Services PCL BDULF
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bangkok Dusit Medical Services PCL Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0 Mil mean?
Bangkok Dusit Medical Services PCL (BDULF) has a Research & Development of $0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Bangkok Dusit Medical Services PCL and its competitors.
Is Bangkok Dusit Medical Services PCL's Research & Development too high?
Bangkok Dusit Medical Services PCL's current Research & Development is $0 Mil. Overall, Bangkok Dusit Medical Services PCL has a GF Score™ of 65/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Bangkok Dusit Medical Services PCL's Research & Development compare to HCA and THC?
Bangkok Dusit Medical Services PCL's Research & Development of $0 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Healthcare Providers & Services company?
A good Research & Development depends on the Healthcare Providers & Services industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Bangkok Dusit Medical Services PCL and its competitors. Bangkok Dusit Medical Services PCL's current Research & Development is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bangkok Dusit Medical Services PCL stock overvalued right now?
Based on GuruFocus' analysis, Bangkok Dusit Medical Services PCL (BDULF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.98, compared to a current price of $0.56 — trading 42.9% below its estimated fair value. The current Research & Development is $0 Mil. Bangkok Dusit Medical Services PCL's overall GF Score™ is 65/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Bangkok Dusit Medical Services PCL (BDULF), the current Research & Development is $0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Bangkok Dusit Medical Services PCL (BDULF) Overvalued in 2026?

Based on GuruFocus' analysis, Bangkok Dusit Medical Services PCL stock appears to be undervalued. The current stock price of $0.56 is trading 42.9% below its estimated GF Value™ of $0.98. GuruFocus considers Bangkok Dusit Medical Services PCL to be Significantly Undervalued.

Key valuation signals for BDULF:

  • Research & Development: $0 Mil
  • GF Value™: $0.98 vs. price of $0.56 (42.9% below fair value)
  • GF Score™: 65/100 with 2 warning signs

No single metric tells the full story. See the BDULF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Bangkok Dusit Medical Services PCL Business Description

Address New Petchburi Road, 2, Soi Soonvijai 7, Bang Kapi, Huaykwang, Bangkok, THA, 10310
Bangkok Dusit Medical Services PCL operates a network of private hospitals in Thailand and some overseas markets, under the Bangkok Hospital, Phyathai Hospital, Samitivej Hospital, Paolo Hospital, BNH Hospital, and Royal International Hospital brands. The company has two business segments, namely hospital operations and other businesses that support hospital business, such as medical laboratories, production and distribution of pharmaceutical products/medical equipment/saline, pharmacies, asset management for healthcare business, accounting services, technology and information services, training business, and insurance broker. The company's hospital operations generate the vast majority of its revenue.
65GF Score

Get the complete analysis for BDULF

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.56
Price
$0.98
GF Value